Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2722 in Chronic Sinusitis With or Without Nasal Polyps
NCT06089278Phase 2Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TQH2722 in sinusitis (3 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Nasal Polyp Score at 16 weeks and Lund-Mackay Score on Sinus CT Scan at 16 weeks. Started Dec 2023; status: completed.
02
Drugs
TQH2722
03
Conditions
sinusitis
Beyond the preview
Go deeper on NCT06089278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089278.